600572 康恩贝
已收盘 12-08 15:00:00
资讯
新帖
简况
康恩贝（600572）披露关于减少注册资本通知债权人的公告，11月28日股价下跌0.65%
证券之星 · 11-28
康恩贝（600572）披露关于减少注册资本通知债权人的公告，11月28日股价下跌0.65%
康恩贝（600572）披露2022年股票期权激励计划首次授予股票期权第二个行权期自主行权实施公告，11月24日股价上涨0.44%
证券之星 · 11-24
康恩贝（600572）披露2022年股票期权激励计划首次授予股票期权第二个行权期自主行权实施公告，11月24日股价上涨0.44%
浙金信托接手大连万达商管旗下两家公司
澎湃新闻 · 11-24
浙金信托接手大连万达商管旗下两家公司
每周股票复盘：康恩贝（600572）集团减持1%股份至12.792%
证券之星 · 11-16
每周股票复盘：康恩贝（600572）集团减持1%股份至12.792%
11月11日康恩贝发布公告，股东减持470.26万股
证券之星 · 11-11
11月11日康恩贝发布公告，股东减持470.26万股
每周股票复盘：康恩贝（600572）股东减持2376.16万股
证券之星 · 11-09
每周股票复盘：康恩贝（600572）股东减持2376.16万股
11月6日康恩贝发布公告，股东减持2376.16万股
证券之星 · 11-06
11月6日康恩贝发布公告，股东减持2376.16万股
每周股票复盘：康恩贝（600572）Q3净利增69.11%，股东户数降3.48%
证券之星 · 11-02
每周股票复盘：康恩贝（600572）Q3净利增69.11%，股东户数降3.48%
康恩贝(600572)9月30日股东户数8.67万户，较上期减少3.48%
证券之星 · 10-28
康恩贝(600572)9月30日股东户数8.67万户，较上期减少3.48%
康恩贝最新公告：第三季度净利润为2.3亿元同比增长69.11%
证券之星 · 10-28
康恩贝最新公告：第三季度净利润为2.3亿元同比增长69.11%
康恩贝最新公告：腺苷钴胺胶囊拟中标第十一批全国药品集中采购
证券之星 · 10-28
康恩贝最新公告：腺苷钴胺胶囊拟中标第十一批全国药品集中采购
每周股票复盘：康恩贝（600572）副总裁沈旗因工作调整离任
证券之星 · 10-19
每周股票复盘：康恩贝（600572）副总裁沈旗因工作调整离任
康恩贝（600572）披露2022年股票期权激励计划首次授予股票期权第一个行权期限制行权期间的提示性公告，10月17日股价下跌0.45%
证券之星 · 10-17
康恩贝（600572）披露2022年股票期权激励计划首次授予股票期权第一个行权期限制行权期间的提示性公告，10月17日股价下跌0.45%
康恩贝副总裁沈旗离任
北京商报 · 10-17
康恩贝副总裁沈旗离任
每周股票复盘：康恩贝（600572）三季度行权360.5万股
证券之星 · 10-12
每周股票复盘：康恩贝（600572）三季度行权360.5万股
康恩贝（600572）披露2025年第三季度股票期权激励计划自主行权结果暨股份变动公告，10月9日股价上涨0.92%
证券之星 · 10-09
康恩贝（600572）披露2025年第三季度股票期权激励计划自主行权结果暨股份变动公告，10月9日股价上涨0.92%
每周股票复盘：康恩贝（600572）将召开2025年半年度业绩说明会
证券之星 · 09-21
每周股票复盘：康恩贝（600572）将召开2025年半年度业绩说明会
集采失标又陷质量危机，康恩贝年销3.5亿元核心化药被暂停采购
微博财经-财道工作室 · 09-18
集采失标又陷质量危机，康恩贝年销3.5亿元核心化药被暂停采购
康恩贝(600572.SH)：超短期融资券和中期票据获准注册
格隆汇 · 09-10
康恩贝(600572.SH)：超短期融资券和中期票据获准注册
康恩贝：子公司吸入用复方异丙托溴铵溶液获药品注册证书
同花顺财经 · 09-08
康恩贝：子公司吸入用复方异丙托溴铵溶液获药品注册证书
公司概况
公司名称：
浙江康恩贝制药股份有限公司
所属行业：
医药制造业
上市日期：
2004-04-12
主营业务：
浙江康恩贝制药股份有限公司的主营业务是药品、中药饮片及大健康产品的研发、制造及销售。公司的主要产品是中成药、中药材与中药饮片、中药保健品及中药提取物、中药OTC及中药处方药业务。
发行价格：
8.25
{"stockData":{"symbol":"600572","market":"SH","secType":"STK","nameCN":"康恩贝","latestPrice":4.65,"timestamp":1765177201000,"preClose":4.72,"halted":0,"volume":33463310,"delay":0,"changeRate":-0.0148,"floatShares":2520000000,"shares":2527000000,"eps":0.2724,"marketStatus":"已收盘","change":-0.07,"latestTime":"12-08 15:00:00","open":4.72,"high":4.74,"low":4.64,"amount":156000000,"amplitude":0.0212,"askPrice":4.66,"askSize":4021,"bidPrice":4.65,"bidSize":2206,"shortable":0,"etf":0,"ttmEps":0.2724,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765243800000},"marketStatusCode":5,"adr":0,"adjPreClose":4.72,"symbolType":"stock","openAndCloseTimeList":[[1765157400000,1765164600000],[1765170000000,1765177200000]],"highLimit":5.19,"lowLimit":4.25,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2526581971,"isCdr":false,"pbRate":1.66,"roa":"--","peRate":17.070485,"roe":"8.05%","epsLYR":0.25,"committee":0.091675,"marketValue":11749000000,"turnoverRate":0.0133,"status":1,"floatMarketCap":11717000000},"requestUrl":"/m/hq/s/600572/wiki","defaultTab":"wiki","newsList":[{"id":"2586733559","title":"康恩贝（600572）披露关于减少注册资本通知债权人的公告，11月28日股价下跌0.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586733559","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586733559?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:27","pubTimestamp":1764340039,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘，康恩贝报收于4.62元，较前一交易日下跌0.65%，最新总市值为116.73亿元。公司近日发布公告称，浙江康恩贝制药股份有限公司因注销回购股份，注册资本将由2,570,037,319元减少至2,506,458,271元，总股本减少63,579,048股。公司已于2025年10月27日召开董事会会议，于2025年11月13日召开临时股东大会，审议通过相关议案。申报方式包括现场递交或邮寄，申报期间为2025年11月29日至2026年1月12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800040500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0060","BK0012","BK0097","BK0028","600572"],"gpt_icon":0},{"id":"2585549854","title":"康恩贝（600572）披露2022年股票期权激励计划首次授予股票期权第二个行权期自主行权实施公告，11月24日股价上涨0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585549854","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585549854?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:26","pubTimestamp":1763994384,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，康恩贝报收于4.58元，较前一交易日上涨0.44%，最新总市值为115.72亿元。该股当日开盘4.59元，最高4.64元，最低4.57元，成交额达1.57亿元，换手率为1.36%。近日，浙江康恩贝制药股份有限公司发布关于2022年股票期权激励计划首次授予股票期权第二个行权期自主行权实施的公告。行权起始日为2025年11月28日，行权期限为2025年11月28日至2026年11月27日间的交易日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0097","BK0060","BK0012","BK0028","600572","BK0239"],"gpt_icon":0},{"id":"2585345255","title":"浙金信托接手大连万达商管旗下两家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2585345255","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585345255?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:34","pubTimestamp":1763973240,"startTime":"0","endTime":"0","summary":"11月24日，据天眼查披露的信息显示，11月21日，大连万颛企业管理有限公司发生工商变更，原股东大连万达商业管理集团股份有限公司退出，新增苏州联商柒号商业管理有限公司为全资股东，同时法定代表人、主要人员均有所变更。 另外，苏州联商柒号商业管理有限公司还接手了大连万达商业管理集团股份有限公司旗下的大连统南企业管理有限责任公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-11-24/doc-infynvux5750729.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-11-24/doc-infynvux5750729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0102","BK0052","000411","BK0074","LU1508157978.USD","BK0118","LU2663582299.SGD","LU1580142542.USD","BK0272","BK0060","BK0012","LU1781817850.SGD","600120","BK0009","BK0143","600572","BK0097","601995","BK0239","BK0250","BK0028","BK0276","BK0188"],"gpt_icon":0},{"id":"2583651153","title":"每周股票复盘：康恩贝（600572）集团减持1%股份至12.792%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651153","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651153?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:40","pubTimestamp":1763235628,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，康恩贝报收于4.83元，较上周的4.76元上涨1.47%。本周，康恩贝11月14日盘中最高价报4.87元。本周关注点股本股东变化：康恩贝集团减持1.000%股份，持股比例降至12.792%。减持完成后，康恩贝集团及一致行动人胡季强合计持股比例为12.792%。关于2022年股票期权激励计划部分股票期权注销完成的公告因激励对象退休、离职或绩效考核未达标，康恩贝于2025年11月6日决定注销202.92万份已获授但未行权的股票期权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","600572","BK0239","BK0188","BK0097","BK0012"],"gpt_icon":0},{"id":"2582368928","title":"11月11日康恩贝发布公告，股东减持470.26万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582368928","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582368928?lang=zh_cn&edition=full","pubTime":"2025-11-11 19:01","pubTimestamp":1762858882,"startTime":"0","endTime":"0","summary":"证券之星消息，11月11日康恩贝发布公告《康恩贝:股东减持股份结果公告》，其股东康恩贝集团有限公司于2025年11月7日至2025年11月11日间合计减持470.26万股，占公司目前总股本的0.1861%，变动期间该股股价上涨0.84%，截止11月11日收盘报4.8元。股东增减持详情见下表：根据康恩贝2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100032914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600572","BK0188","BK0060","BK0097","BK0012","BK0239"],"gpt_icon":0},{"id":"2582866724","title":"每周股票复盘：康恩贝（600572）股东减持2376.16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582866724","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582866724?lang=zh_cn&edition=full","pubTime":"2025-11-09 02:18","pubTimestamp":1762625894,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，康恩贝报收于4.76元，较上周的4.68元上涨1.71%。本周关注点股本股东变化：股东胡季强、康恩贝集团有限公司合计减持2376.16万股，占总股本0.9411%。期间股价上涨6.73%，截至11月6日收盘报4.76元。康恩贝集团及其一致行动人胡季强持股比例由13.944%降至12.992%，权益变动触及1%刻度。胡季强减持3,221,600股，康恩贝集团减持20,540,000股，均通过集中竞价交易完成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","600572","BK0097","BK0028","BK0060","BK0188"],"gpt_icon":0},{"id":"2581417068","title":"11月6日康恩贝发布公告，股东减持2376.16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581417068","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581417068?lang=zh_cn&edition=full","pubTime":"2025-11-06 18:01","pubTimestamp":1762423289,"startTime":"0","endTime":"0","summary":"证券之星消息，11月6日康恩贝发布公告《康恩贝:关于持股5%以上股东权益变动触及1%刻度的提示性公告》，其股东胡季强、康恩贝集团有限公司于2025年9月4日至2025年11月6日间合计减持2376.16万股，占公司目前总股本的0.9411%，变动期间该股股价上涨6.73%，截止11月6日收盘报4.76元。股东增减持详情见下表：根据康恩贝2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600028557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0188","BK0097","600572","BK0239","BK0012","BK0028"],"gpt_icon":0},{"id":"2580475351","title":"每周股票复盘：康恩贝（600572）Q3净利增69.11%，股东户数降3.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580475351","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580475351?lang=zh_cn&edition=full","pubTime":"2025-11-02 02:43","pubTimestamp":1762022590,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，康恩贝报收于4.68元，较上周的4.47元上涨4.7%。本周，康恩贝10月31日盘中最高价报4.7元。股本股东变化截至2025年9月30日，康恩贝股东户数为8.67万户，较6月30日减少3128.0户，减幅3.48%。业绩披露要点康恩贝2025年三季报显示，主营收入49.76亿元，同比上升1.27%；归母净利润5.84亿元，同比上升12.65%；扣非净利润4.31亿元，同比上升1.61%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0028","BK0060","BK0239","BK0012","BK0188","BK0097"],"gpt_icon":0},{"id":"2578350249","title":"康恩贝(600572)9月30日股东户数8.67万户，较上期减少3.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578350249","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578350249?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:17","pubTimestamp":1761643057,"startTime":"0","endTime":"0","summary":"证券之星消息，近日康恩贝披露，截至2025年9月30日公司股东户数为8.67万户，较6月30日减少3128.0户，减幅为3.48%。在中药行业个股中，康恩贝股东户数高于行业平均水平，截至9月30日，中药行业平均股东户数为5.36万户。从股价来看，2025年6月30日至2025年9月30日，康恩贝区间跌幅为0.68%，在此期间股东户数减少3128.0户，减幅为3.48%。根据统计，康恩贝2025年6月30日至2025年9月30日，主力资金净流出2.68亿元，游资资金净流入6198.78万元，散户资金净流入2.06亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800030738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","BK0239","600572","BK0028","BK0012","BK0060"],"gpt_icon":0},{"id":"2578935422","title":"康恩贝最新公告：第三季度净利润为2.3亿元同比增长69.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578935422","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578935422?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:14","pubTimestamp":1761642844,"startTime":"0","endTime":"0","summary":"康恩贝(600572.SH)发布2025年第三季度报告，第三季度营收为16.17亿元，同比增长10.42%；净利润为2.3亿元，同比增长69.11%。前三季度净利润为5.84亿元，同比增长12.65%。本期净利润增长主要系本报告期末公司主营业务业绩增长、所持嘉和生物股份期末市值较上年同期市值增加。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800030367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572"],"gpt_icon":0},{"id":"2578356969","title":"康恩贝最新公告：腺苷钴胺胶囊拟中标第十一批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2578356969","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578356969?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:07","pubTimestamp":1761642442,"startTime":"0","endTime":"0","summary":"康恩贝(600572.SH)公告称，公司全资子公司杭州康恩贝参加了国家组织第十一批药品集中带量采购工作，产品腺苷钴胺胶囊拟中标本次集中采购。中选结果将在联合采购办公室公示后正式发布。腺苷钴胺胶囊适用于巨幼红细胞性贫血等症状，是《国家基本医疗保险、工伤保险和生育保险药品目录（2024年版）》甲类药品。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800029982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","600572","BK0012","BK0097","BK0060"],"gpt_icon":0},{"id":"2576968046","title":"每周股票复盘：康恩贝（600572）副总裁沈旗因工作调整离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2576968046","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576968046?lang=zh_cn&edition=full","pubTime":"2025-10-19 02:50","pubTimestamp":1760813421,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，康恩贝报收于4.46元，较上周的4.42元上涨0.9%。公司公告汇总关于高级管理人员离任的公告浙江康恩贝制药股份有限公司于2025年10月17日收到副总裁沈旗先生递交的书面辞职报告，因工作调整原因，沈旗先生申请辞去公司副总裁职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","BK0239","600572","BK0188","BK0097","BK0060"],"gpt_icon":0},{"id":"2576059602","title":"康恩贝（600572）披露2022年股票期权激励计划首次授予股票期权第一个行权期限制行权期间的提示性公告，10月17日股价下跌0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576059602","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576059602?lang=zh_cn&edition=full","pubTime":"2025-10-17 22:26","pubTimestamp":1760711175,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，康恩贝报收于4.46元，较前一交易日下跌0.45%，最新总市值为112.61亿元。公司近日发布公告称，根据相关规定及公司2025年第三季度报告披露计划，公司将对处于自主行权期间的股票期权实施限制行权。2022年股票期权激励计划首次授予股票期权第一个行权期的可行权期为2024年11月28日至2025年11月27日，期权代码1000000270。本次限制行权期为2025年10月24日至2025年10月29日，期间全部激励对象将限制行权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700038470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","600572","BK0097","BK0012","BK0028","BK0188"],"gpt_icon":0},{"id":"2576036410","title":"康恩贝副总裁沈旗离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2576036410","media":"北京商报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576036410?lang=zh_cn&edition=full","pubTime":"2025-10-17 18:24","pubTimestamp":1760696640,"startTime":"0","endTime":"0","summary":"北京商报讯10月17日，康恩贝发布公告称，公司副总裁沈旗因工作调整原因，向董事会申请辞去副总裁职务。沈旗辞去副总裁职务后，将不再担任公司投资总监职务，仍担任公司控股子公司浙江中医药大学中药饮片有限公司董事长职务。（文章来源：北京商报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-17/doc-infuexsm6211393.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-17/doc-infuexsm6211393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0060","600572","BK0097","BK0239","BK0012","BK0028"],"gpt_icon":0},{"id":"2574683284","title":"每周股票复盘：康恩贝（600572）三季度行权360.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2574683284","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574683284?lang=zh_cn&edition=full","pubTime":"2025-10-12 03:04","pubTimestamp":1760209456,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，康恩贝报收于4.42元，较上周的4.35元上涨1.61%。本周，康恩贝10月10日盘中最高价报4.44元。本周关注点公司公告汇总：2025年第三季度股票期权行权360.4973万股，募集资金1,308.6052万元。截至2025年9月30日，累计行权1,847.2100万股，占第一个行权期可行权数量的82.7173%。股本结构变动后，总股本增至2,524,930,371股，股权分布仍具备上市条件，实际控制人未发生变化。本次行权对公司财务状况和经营成果无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0012","BK0097","BK0188","BK0028","600572","BK0239"],"gpt_icon":0},{"id":"2574541169","title":"康恩贝（600572）披露2025年第三季度股票期权激励计划自主行权结果暨股份变动公告，10月9日股价上涨0.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574541169","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574541169?lang=zh_cn&edition=full","pubTime":"2025-10-09 22:50","pubTimestamp":1760021430,"startTime":"0","endTime":"0","summary":"近日，康恩贝发布《关于2025年第三季度股票期权激励计划自主行权结果暨股份变动公告》。公告显示，2025年第三季度，公司2022年股票期权激励计划首次授予激励对象行权且完成股份过户登记的股票数量合计为360.4973万股，行权方式为自主行权，行权价格为3.63元/股，募集资金1,308.6052万元，用于补充流动资金。截至2025年9月30日，累计行权1,847.2100万股，占第一个行权期可行权数量的82.7173%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900034790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","BK0097","BK0060","BK0188","600572","BK0239"],"gpt_icon":0},{"id":"2569459942","title":"每周股票复盘：康恩贝（600572）将召开2025年半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2569459942","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569459942?lang=zh_cn&edition=full","pubTime":"2025-09-21 03:18","pubTimestamp":1758395896,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，康恩贝报收于4.44元，较上周的4.51元下跌1.55%。本周，康恩贝9月17日盘中最高价报4.53元。康恩贝当前最新总市值112.08亿元，在中药板块市值排名22/67，在两市A股市值排名1683/5153。公司已于2025年8月28日在上海证券交易所网站发布2025年半年度报告。说明会期间，投资者可通过该平台在线参与并提问。会后可通过该平台查看会议情况。联系人：陈芳、王洁，电话：0571-87774828、0571-87774827。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100000715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0060","BK0188","BK0097","BK0028","BK0239","BK0012"],"gpt_icon":0},{"id":"2568540827","title":"集采失标又陷质量危机，康恩贝年销3.5亿元核心化药被暂停采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2568540827","media":"微博财经-财道工作室","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568540827?lang=zh_cn&edition=full","pubTime":"2025-09-18 21:11","pubTimestamp":1758201060,"startTime":"0","endTime":"0","summary":"按此前披露数据，金华康恩贝2024年前三季度原料药及制剂业务收入5.3亿元，呼吸系统用药占比超三成，对应年收入规模约2.1亿元。截至2025年9月16日，公司113.84亿元市值在中药板块排名第23位，较2023年行业地位明显下滑。“这次质量风波对康恩贝的打击是双重的。”尽管近三年康恩贝研发投入持续增长，2024年达3.26亿元，同比增长4.35%，实现五年连增。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2025-09-18/doc-infqxrxf8684605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","600572","BK0060","BK0188","BK0012","BK0097","BK0028"],"gpt_icon":0},{"id":"2566796816","title":"康恩贝(600572.SH)：超短期融资券和中期票据获准注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2566796816","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566796816?lang=zh_cn&edition=full","pubTime":"2025-09-10 16:34","pubTimestamp":1757493285,"startTime":"0","endTime":"0","summary":"格隆汇9月10日丨康恩贝(600572.SH)公布，近日，公司收到交易商协会出具的《接受注册通知书》（中市协注[2025]SCP252号）、（中市协注[2025]MTN850号），交易商协会同意接受公司超短期融资券和中期票据注册。现将主要内容公告如下：公司超短期融资券注册金额为10亿元，注册额度自《接受注册通知书》落款之日起2年内有效；公司中期票据注册金额为10亿元，注册额度自《接受注册通知书》落款之日起2年内有效。\n\n\r\n 责任编辑：山上","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/09/10163453050552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0012","BK0060","600572","BK0188","BK0028","BK0097","BK0239"],"gpt_icon":0},{"id":"2565436509","title":"康恩贝：子公司吸入用复方异丙托溴铵溶液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2565436509","media":"同花顺财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565436509?lang=zh_cn&edition=full","pubTime":"2025-09-08 16:13","pubTimestamp":1757319202,"startTime":"0","endTime":"0","summary":"康恩贝公告，全资子公司金华康恩贝生物制药有限公司收到国家药品监督管理局核准签发的吸入用复方异丙托溴铵溶液《药品注册证书》。该药品适用于治疗气道阻塞性疾病有关的可逆性支气管痉挛，由勃林格殷格翰药业有限公司开发，1994年首次在法国获批上市。金华康恩贝于2024年1月提交注册申请并获得受理，目前已投入研发费用约790万元。2024年，国内相应终端市场销售金额达2.4亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/09/08161352993793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["600572","BK0239","BK0097","BK0028","BK0012","BK0188","BK0060"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765227072036,"stockEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0231},{"period":"3month","weight":0.031},{"period":"6month","weight":0.0315},{"period":"1year","weight":-0.0068},{"period":"ytd","weight":0.0315}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0184},{"period":"3month","weight":0.0307},{"period":"6month","weight":0.1534},{"period":"1year","weight":0.1528},{"period":"ytd","weight":0.1708}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江康恩贝制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"79822人(较上一季度增加0.20%)","perCapita":"31568股","listingDate":"2004-04-12","address":"浙江省金华市兰溪市康恩贝大道1号","registeredCapital":"252658万元","survey":" 浙江康恩贝制药股份有限公司的主营业务是药品、中药饮片及大健康产品的研发、制造及销售。公司的主要产品是中成药、中药材与中药饮片、中药保健品及中药提取物、中药OTC及中药处方药业务。","listedPrice":8.25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康恩贝(600572)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康恩贝(600572)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康恩贝,600572,康恩贝股票,康恩贝股票老虎,康恩贝股票老虎国际,康恩贝行情,康恩贝股票行情,康恩贝股价,康恩贝股市,康恩贝股票价格,康恩贝股票交易,康恩贝股票购买,康恩贝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康恩贝(600572)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康恩贝(600572)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}